Trials / Completed
CompletedNCT04883528
Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Duke University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effect of sacubitril/valsartan versus placebo on markers of cardiac injury, structure, and function among patients who recovered from acute COVID-19 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sacubitril / Valsartan Oral Tablet [Entresto] | sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally. |
| DRUG | Placebo | sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally. |
Timeline
- Start date
- 2021-08-06
- Primary completion
- 2023-06-13
- Completion
- 2023-06-13
- First posted
- 2021-05-12
- Last updated
- 2024-07-03
- Results posted
- 2024-07-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04883528. Inclusion in this directory is not an endorsement.